Home Cart Sign in  
Chemical Structure| 1393466-87-9 Chemical Structure| 1393466-87-9
Chemical Structure| 1393466-87-9
Product Citations

Alternative Products

Product Details of PLX8394

CAS No. :1393466-87-9
Formula : C25H21F3N6O3S
M.W : 542.53
SMILES Code : O=C(C1=C(F)C(NS(=O)(N2CC[C@@H](F)C2)=O)=CC=C1F)C3=CNC4=C3C=C(C=N4)C5=CN=C(C6CC6)N=C5
MDL No. :MFCD29472263
InChI Key :YYACLQUDUDXAPA-MRXNPFEDSA-N
Pubchem ID :90116675

Safety of PLX8394

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of PLX8394

MAPK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description Reference
RT3 cells 10 μM 24 hours PLX8394 significantly inhibited TGF-β signaling, reduced phosphorylation of Smad2 and TGF-β receptor II, as well as p38 activity, MMP-1 and MMP-13 synthesis, and decreased laminin-332 accumulation. PMC10691969
HaCaT cells 10 μM 24 hours PLX8394 completely prevented TGF-β-induced Smad2 phosphorylation in both HaCaT and RT3 cells. PMC10691969
A2058 melanoma cells 10 μM 4 hours and 18 hours PLX8394 blocked Smad2 activation in A2058 melanoma cells. PMC10691969
Human Dermal Fibroblasts (HDF) 2 µM 18 hours To evaluate the effect of PLX8394 on the proliferative state of HDF, results showed that PLX8394 did not increase cell proliferation PMC8686565
HEK293T cells 1 µM 4 hours PLX8394 failed to induce BRAF/RAF1 heterodimers, indicating its inhibitory effect on RAF dimerization PMC10265822
HEK293 cells 1 μM 15 minutes Assess the impact of PLX8394 on BRAF-V600E KinCon reporter dynamics, showing that PLX8394 exposure promotes an immediate closing event. PMC7733820
HEK293 cells 1 nM Assess the impact of PLX8394 on BRAF-N581S KinCon reporter dynamics, showing an immediate closing effect with the lowest dose of PLX8394. PMC7733820
SK-MEL-239 cells 39 nM 1 hour PLX8394 inhibited p-ERK in SK-MEL-239 cells with an IC75 of 39 nM PMC6404779
SK-MEL-239 C4 cells 158 nM 1 hour PLX8394 inhibited p-ERK in SK-MEL-239 C4 cells with an IC75 of 158 nM PMC6404779
293H (NRAS Q61K) cells 100–300 nM 1 hour PLX8394 significantly reduced the levels of RAS-dependent full-length BRAF/BRAF or BRAF/CRAF dimers and RAS-independent BRAF dimers (p61 BRAF) in 293H (NRAS Q61K) cells with an IC50 of 100–300 nM PMC6404779
LM-COL-1 cells 1 μM 6 h PLX8394 had minimal effect on pMEK and pERK, while vemurafenib caused a significant increase in pMEK and pERK PMC5490236
ALA cells 1 μM 6 h PLX8394 had minimal effect on pMEK and pERK, while vemurafenib caused a significant increase in pMEK and pERK PMC5490236
LS513 cells 1 μM 6 h PLX8394 had minimal effect on pMEK and pERK, while vemurafenib caused a significant increase in pMEK and pERK PMC5490236
HCT 116 cells 1 μM 6 h PLX8394 had minimal effect on pMEK and pERK, while vemurafenib caused a significant increase in pMEK and pERK PMC5490236
LIM2405 cells 1 μM 6 h Both PLX8394 and vemurafenib reduced pMEK and pERK levels PMC5490236
COLO 201 cells 1 μM 6 h Both PLX8394 and vemurafenib reduced pMEK and pERK levels PMC5490236

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description Reference
SCID/SCID mice Human cSCC xenograft model Oral 150 mg/kg Once daily for 18 days PLX8394 significantly suppressed the growth of human cSCC xenograft tumors and reduced collagen degradation in the tumors. PMC10691969
SCID/SCID mice human cSCC xenograft model Oral gavage 150 mg/kg once daily for 18 days Significantly inhibits the growth of human cSCC tumors and reduces in vivo collagen degradation PMC10691969
SCID/SCID mice cSCC xenograft model Oral 150 mg/kg Once daily for 18 days PLX8394 significantly suppressed the growth of cSCC xenograft tumors and reduced collagen degradation in tumors, indicating its therapeutic potential for cSCC. PMC10691969
NOD/SCID mice fibroblastoma model Oral 200 mg/kg twice a day until the experimental endpoint To evaluate the inhibitory effect of PLX8394 on fibroblastomas induced by BRAF mutants, results showed that PLX8394 significantly inhibited tumor growth PMC11780520
Nude mice Melanoma xenograft model Oral 50 mg/kg Twice daily, continuous treatment PLX8394 was well tolerated in melanoma xenograft models and effectively inhibited tumor growth at a dose of 50 mg/kg PMC6404779

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02012231 Melanoma|Thyroid Cancer|Colore... More >>ctal Cancer|Non-small Cell Lung Cancer|Cholangiocarcinoma|Histiocytosis|Hairy Cell Leukemia Less << PHASE1 TERMINATED 2025-06-15 Scottsdale Healthcare, Scottsd... More >>ale, Arizona, 85258, United States|Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States|Evergreen Hematology & Oncology, Spokane, Washington, 99218, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.84mL

0.37mL

0.18mL

9.22mL

1.84mL

0.92mL

18.43mL

3.69mL

1.84mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories